PER-055-16
Completed
N/A
A STUDY TO EVALUATE THE EFFECT OF DAPAGLIFLOZIN ON RENAL OUTCOMES AND CARDIOVASCULAR MORTALITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- -N19 Unspecified kidney failure
- Sponsor
- ASTRAZENECA PERU S.A.,
- Enrollment
- 218
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Provision of signed informed consent prior to any study specific procedures
- •2\. Female or male aged ≥18 years at the time of consent
- •3\. eGFR ≥25 and ≤75 mL/min/1\.73m2 (CKD\-EPI Formula) at visit 1
- •4\. UACR ≥200 and ≤5000 mg/g at visit 1
- •5\. Stable, and for the patient maximum tolerated labelled daily dose, treatment with ACE\-I or ARB for at least 4 weeks before visit 1, if not medically contraindicated
Exclusion Criteria
- •Exclusion criteria is shared in Section 3\.2 of the protocol (pages 26\-27\) there are 17 exclusion criteria
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
Dapa-CKDChronic Kidney DiseaseJPRN-jRCT2080223905AstraZeneca KK240
Active, Not Recruiting
Phase 1
A study to evaluate if dapagliflozin can prevent the gradual loss of kidney function and improve survival for patients with chronic kidney disease.Chronic kidney disease (CKD)MedDRA version: 21.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2016-003896-24-DKAstraZeneca AB4,000
Active, Not Recruiting
Phase 1
A study to evaluate if dapagliflozin can prevent the gradual loss of kidney function and improve survival for patients with chronic kidney disease.Chronic kidney disease (CKD)Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2016-003896-24-HUAstraZeneca AB4,000
Active, Not Recruiting
Phase 1
A study to evaluate if dapagliflozin can prevent the gradual loss of kidney function and improve survival for patients with chronic kidney disease.Chronic kidney disease (CKD)Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2016-003896-24-DEAstraZeneca AB4,000
Active, Not Recruiting
Phase 1
A study to evaluate if dapagliflozin can prevent the gradual loss of kidney function and improve survival for patients with chronic kidney disease.EUCTR2016-003896-24-SEAstraZeneca AB4,000